Premium
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies
Author(s) -
Seno H.,
Nakase H.,
Chiba T.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02471.x
Subject(s) - famotidine , mosapride , medicine , gastroenterology , visual analogue scale , regimen , omeprazole , anesthesia
Summary Background : The treatment of functional dyspepsia is controversial. Aim : The purpose of this paper is to clarify the initial effect of prokinetic, acid suppression and antianxiety treatment for functional dyspepsia patients. Patients and methods : Sixty‐four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8‐week treatment. Individual functional dyspepsia symptoms were evaluated with 4 cm visual analogue scale before and at 2, 4 and 8 weeks after treatment. Results : Among 64 enrolled patients, 62 completed the study. Within 2 weeks, visual analogue scale score in the mosapride‐treated group decreased from 2.29 ±0.14 to 1.57 ± 0.20; in the famotidine from 2.04 ± 0.16 to 1.09 ± 0.12 (mean ± S.E.). Therefore, there were significant improvements of functional dyspepsia symptoms in mosapride‐ and famotidine‐treated patients ( P <0.01). Furthermore, famotidine was significantly more effective than mosapride ( P < 0.05). On the contrary, visual analogue scale score in the tandospirone therapy was 2.23 ± 0.20 and 2.13 ± 0.22 before and at 2 weeks, respectively, without any significant improvement. Conclusions : A treatment regimen of famotidine at 40 mg/day had a significant favourable effect on the clinical outcome in functional dyspepsia patients.